EBITDA Margin % is calculated as EBITDA divided by its Revenue. Walpar Nutritions's EBITDA for the
six
months ended in Mar. 2024 was ₹28.9 Mil. Walpar Nutritions's Revenue for the
six
months ended in Mar. 2024 was ₹313.8 Mil. Therefore, Walpar Nutritions's EBITDA margin for the quarter that ended in Mar. 2024 was 9.19%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Walpar Nutritions EBITDA Margin % Related Terms
Walpar Nutritions EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Walpar Nutritions's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:WALPAR vs ZTS, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Walpar Nutritions's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Walpar Nutritions EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Walpar Nutritions's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Walpar Nutritions's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Walpar Nutritions (NSE:WALPAR) has a EBITDA Margin % of 9.19% as of Mar. 2024. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Walpar Nutritions and its competitors.
Is Walpar Nutritions' EBITDA Margin % too high?
Walpar Nutritions' current EBITDA Margin % is 9.19%. The Drug Manufacturers industry median EBITDA Margin % is 12.47. Walpar Nutritions' value of 9.19% is 26.3% below this industry median. Overall, Walpar Nutritions has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does Walpar Nutritions' EBITDA Margin % compare to ZTS and VTRS?
Walpar Nutritions' EBITDA Margin % of 9.19% can be compared against companies in the Drug Manufacturers industry. The industry median EBITDA Margin % is 12.47. Walpar Nutritions' value of 9.19% is 26.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Walpar Nutritions's current EBITDA Margin % of 9.19% is 26.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Walpar Nutritions and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Walpar Nutritions's current EBITDA Margin % is 9.19%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Walpar Nutritions stock overvalued right now?
Walpar Nutritions (NSE:WALPAR) has a current EBITDA Margin % of 9.19%. The current EBITDA Margin % is 9.19% and 26.3% below the Drug Manufacturers industry median of 12.47. Walpar Nutritions' overall GF Score™ is 54/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Walpar Nutritions (NSE:WALPAR), the current EBITDA Margin % is 9.19% as of Mar. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Walpar Nutritions Ltd is India-based company, which is engaged in manufacturing and trading of pharmaceutical, nutraceutical, herbal and ayurvedic commodities. It also manufactures various private label/third party brands for different companies across the country and overseas, as well as for their own brand sales. It is a manufacturer of various types of nutraceutical formulation, pharmaceutical ingredients, and pharmaceutical formulations. It specializes in contract manufacturing, raw materials trading, and direct selling. Its portfolio consists of tablets, capsules, powder/sachets, and oral liquids.
54GF Score
Get the complete analysis for NSE:WALPAR
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:WALPAR has been successfully added to your 
